SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (470)8/2/1999 1:50:00 PM
From: John Metcalf  Respond to of 579
 
>I don't think another offer is very likely, though. It's hard to value a biotech without their cooperation. <

Pfizer may be able to assign a value, now that they won't be able to litigate Sibia into oblivion. To PFE, SIBI would be worth litigation costs and possible future royalties (from assay subscribers, and maybe from PFE), plus cash, plus patents and other assets, plus products in development.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2024 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News